Skip to main content
Top
Published in: Clinical Rheumatology 7/2007

01-07-2007 | Brief Report

Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma

Authors: R. Russo, H. Medbury, A. Guiffre, H. Englert, N. Manolios

Published in: Clinical Rheumatology | Issue 7/2007

Login to get access

Abstract

The aetiology and pathogenesis of scleroderma is incompletely understood. Recently, a cell called the fibrocyte has been shown to be derived from circulating monocytes with the ability to produce collagen. The aim of this study was to evaluate differences in the cell surface characteristics of circulating fibrocyte progenitors (monocytes) in patients with limited scleroderma compared to controls. A case-control study was performed in eight patients with limited scleroderma, which were matched with eight controls. Three-colour flow cytometry was used to assess the relative expression of cell surface markers. Statistical analysis then compared the relative expression between the two groups. In this preliminary study, there were no significant differences in the expression of circulating monocyte surface molecules involved with cell transformation, function, or migration presumed to give rise to fibrocytes, in a population of patients with limited scleroderma. Various explanations for the results are discussed.
Literature
1.
go back to reference LeRoy EC, Black C, Fleishmajer R et al (1998) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205 LeRoy EC, Black C, Fleishmajer R et al (1998) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205
2.
go back to reference Douvas A (1996) Pathogenesis: serologic correlates. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams and Wilkins, Baltimore, pp 175–202 Douvas A (1996) Pathogenesis: serologic correlates. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams and Wilkins, Baltimore, pp 175–202
3.
go back to reference White B (1996) Pathogenesis: serologic correlates. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams and Wilkins, Baltimore, pp 229–250 White B (1996) Pathogenesis: serologic correlates. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams and Wilkins, Baltimore, pp 229–250
4.
go back to reference LeRoy EC, McGuire M, Chen N (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro. A possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54:880–889PubMedCrossRef LeRoy EC, McGuire M, Chen N (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro. A possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54:880–889PubMedCrossRef
5.
go back to reference Bucala R, Spiegal LA, Chesney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1:71PubMed Bucala R, Spiegal LA, Chesney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1:71PubMed
6.
go back to reference Abe R, Donnelly S, Peng T, Bucala R, Metz C (2001) Peropheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166:7556–7562PubMed Abe R, Donnelly S, Peng T, Bucala R, Metz C (2001) Peropheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166:7556–7562PubMed
7.
go back to reference Aiba S, Tabata N, Ohtani H, Tagami H (1994) CD34+ spindle-shaped cells selectively disappear from the skin lesions of scleroderma. Arch Dermatol 130:593–597PubMedCrossRef Aiba S, Tabata N, Ohtani H, Tagami H (1994) CD34+ spindle-shaped cells selectively disappear from the skin lesions of scleroderma. Arch Dermatol 130:593–597PubMedCrossRef
8.
go back to reference The Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef The Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
9.
go back to reference Hauser C, Kaya G, Chizzolini C (2004) Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology 209:50–52PubMedCrossRef Hauser C, Kaya G, Chizzolini C (2004) Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis. Dermatology 209:50–52PubMedCrossRef
10.
go back to reference Cowper S, Su L, Bhawan J, Robin H, LeBoit PE (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23(5):383–393PubMedCrossRef Cowper S, Su L, Bhawan J, Robin H, LeBoit PE (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23(5):383–393PubMedCrossRef
11.
go back to reference Pilling D, Buckley CD, Salmon M, Gomer R (2003) Inhibition of fibrocyte differentiation by serum Amyloid P. J Immunol 171(10):5537–5546PubMed Pilling D, Buckley CD, Salmon M, Gomer R (2003) Inhibition of fibrocyte differentiation by serum Amyloid P. J Immunol 171(10):5537–5546PubMed
Metadata
Title
Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma
Authors
R. Russo
H. Medbury
A. Guiffre
H. Englert
N. Manolios
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0461-5

Other articles of this Issue 7/2007

Clinical Rheumatology 7/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine